All Editorials articles
-
OpinionChanging the rules of global chemicals trade
Chemical dumping claims reflect US and China’s focus on national interests ahead of global markets
-
OpinionInhaler propellant switch is worth the effort
Memories of a year spent testing new inhaler valve designs
-
OpinionWe’ll always have Paris… won’t we?
A decade on from Cop21, the Paris agreement has delivered change, but keeping it on track is getting harder
-
OpinionDon’t blame patients for the emissions of their inhalers
Alternatives with lower global warming potential are out there, but the onus can’t be on those suffering
-
OpinionA robotic helping hand
Mechanical labmates are making huge progress, but there are still big challenges to overcome
-
BusinessPfizer and Novo Nordisk’s battle over Metsera
Lawsuits fly in bidding war over developer of next generation weight loss drugs
-
OpinionSpin-out support is stretched thin
University entrepreneurs need more consistent help to bridge the gap betweeen ideas and businesses
-
OpinionA brief intro to altermagnetism
Experiments only directly confirmed the existence of this type of magnetic material last year but it’s already making waves
-
OpinionGoing round in circles over skills
Closing skills gaps in key professional groups requires collaboration between government, industry and educators
-
-
CareersWhy we should stop venerating Nobel laureates
The winners of the Nobel prize in chemistry have all made mistakes – and that’s inspirational
-
OpinionTrump steps up pharma tariff threat
Taxing branded drug imports could hit biotech innovators hardest
-
OpinionSolar cell progress hinges on more than just materials
Solvents are a critical factor in the quest for more sustainable energy
-
OpinionDrowning in a sea of fakery
Addressing rising fraud in the scientific literature is a huge issue that AI is set to exacerbate
-
OpinionA global petrochemical shift
China’s rapid capacity expansion fuels global oversupply, leading plant closures in Europe and elsewhere
-
OpinionIs UK pharma really ‘uninvestable’?
Merck & Co, AstraZeneca (AZ) and Eli Lilly pulling UK projects highlights the precarious position of the country’s life sciences industry
-
OpinionUK biofuels burning out
With UK plants facing closure, what are the options and issues around different renewable fuels?
-
OpinionDeadly fentanyl contamination exposes drug safety challenges
Bacterial contamination in medical fentanyl has killed at least 51 people in Argentina, highlighting pressures on generic drugmakers
-
OpinionThe clean beauty movement highlights wider challenges in balancing chemical risks and benefits
The ‘clean beauty’ movement exemplifies broader challenges in how we evaluate chemical safety, balancing risks against benefits while avoiding regrettable substitutions.
-
BusinessWill oral weight loss drugs challenge injectables?
Pills may offer convenience for manufacturers, but it’s not clear they will overtake existing drugs